Prescription drug · BLA
Enspryng (Satralizumab) NDC 50242-005
Satralizumab 180 mg/1.5mL · Injection, Solution · Subcutaneous · Genentech, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50242-005-01 | 5024200050150242000501 | 1 SYRINGE, PLASTIC in 1 CARTON (50242-005-01) / 1.5 mL in 1 SYRINGE, PLASTICMarketed from Oct 15, 2026 | |
| 50242-005-86 | 5024200058650242000586 | 1 SYRINGE, PLASTIC in 1 CARTON (50242-005-86) / 1.5 mL in 1 SYRINGE, PLASTICMarketed from Oct 15, 2026 · Sample package |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Enspryng
- Generic name (nonproprietary)
- satralizumab
- Active ingredients
- Satralizumab — 180 mg/1.5mL
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Labeler
- Genentech, Inc.NDC labeler code 50242
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761149
- Marketing start
- Listing expires
- Identifiers
- Product ID 50242-005_63a8ff00-ffa2-4f6f-84fb-338e7aa7c160SPL ID 63a8ff00-ffa2-4f6f-84fb-338e7aa7c160SPL set ID 64c156a4-9bad-4d45-a294-0733c141f47bRxCUI 2391555, 2391560, 2755191, 2755195UNII YB18NF020M
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N450242000501followed by a unit qualifier and the quantityPackage 50242-0005-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
ENSPRYNG is an interleukin-6 (IL-6) receptor antagonist indicated for: the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1.1 ) the treatment of thyroid eye disease (TED) regardless of TED activity or duration in adult patients. ( 1.2 ) 1.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. 1.2 Thyroid Eye Disease (TED) ENSPRYNG is indicated for the treatment of thyroid eye disease (TED) regardless of TED activity or duration in adult patients.…
Excerpt only. Read the full label for complete information.
About NDC 50242-005
- What is NDC 50242-005?
- 50242-005 is the product NDC for Enspryng (satralizumab), Satralizumab 180 mg/1.5mL injection, solution, listed with the FDA by Genentech, Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Enspryng (Satralizumab).
- What is the active ingredient?
- Satralizumab.
- Who is the labeler?
- Genentech, Inc., NDC labeler code 50242. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Enspryng?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Enspryng products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Enspryngsatralizumab | Satralizumab 120 mg/mL | Injection, SolutionSubcutaneous | Genentech, Inc. | 50242-007 | 50242-0007-0150242-0007-3350242-0007-55+1 more |
Other NDCs under BLA 761149
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Enspryngsatralizumab | Satralizumab 120 mg/mL | Injection, SolutionSubcutaneous | Genentech, Inc. | 50242-007 |